Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 175.87 Billion KRW | 10.44% |
| 2022 | 159.25 Billion KRW | 26.88% |
| 2021 | 125.51 Billion KRW | 32.96% |
| 2020 | 94.4 Billion KRW | 0.82% |
| 2019 | 93.63 Billion KRW | 40.36% |
| 2018 | 66.7 Billion KRW | 9.0% |
| 2017 | 61.2 Billion KRW | 102.65% |
| 2016 | 30.2 Billion KRW | 7.09% |
| 2015 | 28.2 Billion KRW | -22.1% |
| 2014 | 36.2 Billion KRW | 39.23% |
| 2013 | 26 Billion KRW | -13.33% |
| 2012 | 30 Billion KRW | -15.05% |
| 2011 | 35.31 Billion KRW | -6.84% |
| 2010 | 37.9 Billion KRW | 20.0% |
| 2009 | 31.58 Billion KRW | -3.63% |
| 2008 | 32.77 Billion KRW | 807.46% |
| 2007 | 3.61 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 142.54 Billion KRW | -8.81% |
| 2024 Q1 | 156.32 Billion KRW | -11.12% |
| 2023 FY | 175.87 Billion KRW | 10.44% |
| 2023 Q1 | 159.78 Billion KRW | 0.33% |
| 2023 Q4 | 175.87 Billion KRW | -4.96% |
| 2023 Q3 | 185.06 Billion KRW | 11.28% |
| 2023 Q2 | 166.3 Billion KRW | 4.08% |
| 2022 Q2 | 148.86 Billion KRW | 11.28% |
| 2022 Q4 | 159.25 Billion KRW | 0.23% |
| 2022 Q3 | 158.89 Billion KRW | 6.74% |
| 2022 Q1 | 133.77 Billion KRW | 6.58% |
| 2022 FY | 159.25 Billion KRW | 26.88% |
| 2021 Q3 | 124.07 Billion KRW | -0.48% |
| 2021 FY | 125.51 Billion KRW | 32.96% |
| 2021 Q4 | 125.51 Billion KRW | 1.16% |
| 2021 Q1 | 97.46 Billion KRW | 3.25% |
| 2021 Q2 | 124.67 Billion KRW | 27.92% |
| 2020 Q4 | 94.4 Billion KRW | 0.99% |
| 2020 Q1 | 91.88 Billion KRW | -1.86% |
| 2020 Q2 | 93.85 Billion KRW | 2.14% |
| 2020 Q3 | 93.47 Billion KRW | -0.4% |
| 2020 FY | 94.4 Billion KRW | 0.82% |
| 2019 FY | 93.63 Billion KRW | 40.36% |
| 2019 Q4 | 93.63 Billion KRW | 12.81% |
| 2019 Q2 | 65.24 Billion KRW | 0.23% |
| 2019 Q1 | 65.09 Billion KRW | -2.41% |
| 2019 Q3 | 82.99 Billion KRW | 27.21% |
| 2018 Q3 | 66.71 Billion KRW | -2.19% |
| 2018 FY | 66.7 Billion KRW | 9.0% |
| 2018 Q1 | 66.2 Billion KRW | 8.17% |
| 2018 Q2 | 68.2 Billion KRW | 3.03% |
| 2018 Q4 | 66.7 Billion KRW | -0.0% |
| 2017 Q3 | 60.2 Billion KRW | 1.69% |
| 2017 FY | 61.2 Billion KRW | 102.65% |
| 2017 Q1 | 30.2 Billion KRW | 0.0% |
| 2017 Q4 | 61.2 Billion KRW | 1.66% |
| 2017 Q2 | 59.2 Billion KRW | 96.03% |
| 2016 FY | 30.2 Billion KRW | 7.09% |
| 2016 Q4 | 30.2 Billion KRW | -6.21% |
| 2016 Q3 | 32.2 Billion KRW | 3.21% |
| 2016 Q2 | 31.2 Billion KRW | 10.64% |
| 2016 Q1 | 28.2 Billion KRW | 0.0% |
| 2015 Q3 | 29.7 Billion KRW | -13.16% |
| 2015 Q1 | 35.9 Billion KRW | -0.83% |
| 2015 Q2 | 34.2 Billion KRW | -4.74% |
| 2015 FY | 28.2 Billion KRW | -22.1% |
| 2015 Q4 | 28.2 Billion KRW | -5.05% |
| 2014 Q2 | 32.5 Billion KRW | 20.37% |
| 2014 Q1 | 27 Billion KRW | 3.85% |
| 2014 FY | 36.2 Billion KRW | 39.23% |
| 2014 Q4 | 36.2 Billion KRW | 1.97% |
| 2014 Q3 | 35.5 Billion KRW | 9.23% |
| 2013 Q1 | 29 Billion KRW | -3.33% |
| 2013 FY | 26 Billion KRW | -13.33% |
| 2013 Q3 | 29 Billion KRW | 0.0% |
| 2013 Q2 | 29 Billion KRW | 0.0% |
| 2013 Q4 | 26 Billion KRW | -10.34% |
| 2012 Q4 | 30 Billion KRW | 0.0% |
| 2012 FY | 30 Billion KRW | -15.05% |
| 2012 Q1 | 36 Billion KRW | 0.0% |
| 2011 Q2 | 37.07 Billion KRW | 2.58% |
| 2011 Q3 | 34.5 Billion KRW | -6.95% |
| 2011 FY | 35.31 Billion KRW | -6.84% |
| 2011 Q1 | 36.14 Billion KRW | -4.64% |
| 2010 Q2 | 30.6 Billion KRW | 21.48% |
| 2010 FY | 37.9 Billion KRW | 20.0% |
| 2010 Q1 | 25.19 Billion KRW | -20.23% |
| 2010 Q4 | 37.9 Billion KRW | 20.75% |
| 2010 Q3 | 31.39 Billion KRW | 2.56% |
| 2009 Q2 | 33.97 Billion KRW | -2.95% |
| 2009 Q3 | 31.83 Billion KRW | -6.31% |
| 2009 Q1 | 35 Billion KRW | 6.8% |
| 2009 FY | 31.58 Billion KRW | -3.63% |
| 2009 Q4 | 31.58 Billion KRW | -0.76% |
| 2008 FY | 32.77 Billion KRW | 807.46% |
| 2008 Q2 | 21.84 Billion KRW | 32.91% |
| 2008 Q4 | 32.77 Billion KRW | 1.45% |
| 2008 Q3 | 32.31 Billion KRW | 47.91% |
| 2008 Q1 | 16.43 Billion KRW | 355.03% |
| 2007 Q3 | 2.5 Billion KRW | 0.0% |
| 2007 Q4 | 3.61 Billion KRW | 44.48% |
| 2007 FY | 3.61 Billion KRW | 0.0% |
| 2007 Q1 | 2.5 Billion KRW | 0.0% |
| 2007 Q2 | 2.5 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -346.313% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 74.58% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 53.966% |
| HANDOK Inc. | 300.01 Billion KRW | 41.376% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -473.605% |
| Yuhan Corporation | 230.07 Billion KRW | 23.555% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 56.755% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -29435.41% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 69.298% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -13528.447% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -106.528% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -306.443% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -94.38% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -562.868% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -346.313% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -73759.704% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 21.85% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 2.828% |
| JW Holdings Corporation | 554.58 Billion KRW | 68.286% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 19.263% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 19.969% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -3.288% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -281.091% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -348.615% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -107.0% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -346.313% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 25.362% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 62.554% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -3.288% |
| Yuhan Corporation | 230.07 Billion KRW | 23.555% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -1.646% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -162.969% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 62.407% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -3.288% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -48.248% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -336.002% |
| CKD Bio Corp. | 146.92 Billion KRW | -19.705% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -20.424% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -264.476% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -27727.857% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -281.091% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 62.422% |
| Boryung Corporation | 204.21 Billion KRW | 13.876% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -121.547% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -106.528% |
| JW Lifescience Corporation | 46.31 Billion KRW | -279.763% |